Ireland - English - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - valganciclovir - film-coated tablet - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir

Malta - English - Medicines Authority

accord healthcare limited - valaciclovir hydrochloride - film-coated tablet - valaciclovir hydrochloride 450 mg - antivirals for systemic use

Canada - English - Health Canada

cheplapharm arzneimittel gmbh - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Canada - English - Health Canada

apotex inc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - valganciclovir - film-coated tablet - 450 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - valganciclovir - film-coated tablet - 450 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis:  valganciclovir for oral solution is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)] .   prevention of cmv disease:  valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies ( 14.1)] . prevention of cmv disease:  valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies ( 14.2)] . valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant h

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies  (14.1)]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies  (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2) ]. valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1)]. risk summary after o

United States - English - NLM (National Library of Medicine)

american health packaging - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir for oral solution is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)]. valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adv

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -